PD-L1 (CPS) >= 5
About
Biomarker Type: Protein expression
Present: True
Marker: PD-L1
Unit: Combined Positive Score (CPS)
Equality: >=
Value: 5
Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
Therapeutic response
Precision oncology relationships for therapeutic response involving this biomarker.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | HER2-negative, PD-L1 (CPS) >= 5 | Esophageal Adenocarcinoma | Fluorouracil, Nivolumab, Oxaliplatin | |
| Sensitivity (+) | HER2-negative, PD-L1 (CPS) >= 5 | Esophageal Adenocarcinoma | Nivolumab, Oxaliplatin | |
| Sensitivity (+) | HER2-negative, PD-L1 (CPS) >= 5 | Esophagogastric Adenocarcinoma | Fluorouracil, Nivolumab, Oxaliplatin | |
| Sensitivity (+) | HER2-negative, PD-L1 (CPS) >= 5 | Esophagogastric Adenocarcinoma | Nivolumab, Oxaliplatin | |
| Sensitivity (+) | HER2-negative, PD-L1 (CPS) >= 5 | Adenocarcinoma of the Gastroesophageal Junction | Fluorouracil, Nivolumab, Oxaliplatin | |
| Sensitivity (+) | HER2-negative, PD-L1 (CPS) >= 5 | Adenocarcinoma of the Gastroesophageal Junction | Nivolumab, Oxaliplatin |